Precision Antibody’s proprietary technology develops fully human antibodies in ~60 days
Precision Antibody has an exclusive license agreement with trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci. Precision Antibody has developed a proprietary method to develop a strong immune response against therapeutic targets in three weeks, enabling fully human therapeutic antibody development in ~60 days. Through comprehensive, high-throughput DNA sequencing, it has been shown that the human Ig repertoire is well recapitulated in TC-mAb mice. TC-mAb mice have more subsets of antigen-specific plasmablast and plasma cells than wild-type mice, thus leading to efficient hybridoma production.
To learn more about TC-mAb mice, click below to read the full Nature article.
Led by innovative minds in immunology and the antibody development field, Precision Antibody has been an industry leader for over 20 years. We not only implement a cutting-edge technique in antigen design, antibody development, production, and other analyses, but we are also constantly working on ways to improve and advance technology to match the ever-changing world of science. If you are interested in learning more about Precision Antibody’s Custom Antibody development, contact us today.